NVP-BEZ235 is an inhibitor of both
phosphatidylinositol 3-kinase (PI3K) and
mammalian target of rapamycin complex 1/2 (
mTORC1/2), and its antitumor activity is expected to be higher than that of
mTORC1 inhibitors because it inhibits the upregulation of pAkt through
mTORC2. We examined the efficacy of intravesical
NVP-BEZ235 therapy in the treatment of
bladder cancer using an orthotopic
bladder cancer model. The cytotoxic effects of various concentrations of
NVP-BEZ235 in MBT-2 cells were examined using a WST assay. The expression of pAkt, pS6 and p4EBP1 was evaluated in MBT-2 cells treated with
NVP-BEZ235 using western blotting. Orthotopic models were established by implanting MBT-2 cells into the bladders of female C3H/He mice. We assigned C3H/He mice to 2 groups: a control group treated with vehicle control (n=15), and a group intravesically administered 40 µM (18.78 mg/l) of
NVP-BEZ235 (n=15).
NVP-BEZ235 inhibited the viability of MBT-2 cells in a dose-dependent manner. Furthermore, the expression of pAkt, pS6, and p4EBP1 was inhibited in NVP-BEZ235-treated MBT-2 cells. Bladder weights were significantly lower in the NVP-BEZ235-treated group than in the control group (P<0.05). An analysis of the
tumor tissues revealed that the
NVP-BEZ235 treatment strongly reduced pAkt, pS6 and p4EBP1 levels. An immunohistochemical analysis showed that
NVP-BEZ235 significantly inhibited the expression of pS6. Intravesically administered
NVP-BEZ235 exerted significant antitumor effects in the orthotopic
bladder cancer model by inhibiting the PI3K/Akt/mTOR pathway. The
intravesical instillation of a dual PI3K/
mTORC1/2 inhibitor may represent a novel
therapy for the treatment of
bladder cancer.